CEO Executive AssistantA pharmaceutical product launch is one of the most visible and consequential events in any CEO’s tenure. For organizations that have invested years and billions of dollars in developing a new therapy, the launch period is when the commercial value of that investment is realized, or not. The pressure on the CEO to ensure launch success is immense.
But the CEO’s role in a product launch is not to manage the launch. It is to set the conditions for the launch organization to succeed and to represent the launch to external stakeholders with authority and credibility. This playbook defines what the CEO does personally during a product launch, what they delegate to whom, and what governance mechanisms ensure the launch is on track without requiring CEO operational involvement.
T-minus 18 Months: Foundation Delegation
Eighteen months before anticipated approval is when the most important delegation decisions are made. The CEO who defers these decisions until T-minus six months or T-minus three months will find the launch organization scrambling to build governance structures under launch pressure.
CEO Actions at T-18:
- Confirm the CCO has the authority, resources, and organizational backing to lead the launch organization
- Commission a launch readiness assessment from the commercial leadership team
- Approve the overall launch investment budget in principle
- Confirm the Launch Steering Committee structure and chair it has a CCO, not the CEO
- Set the top three to five CEO priorities for the launch period (these should be external: investor communications, key payer relationships, KOL visibility, media)
Delegate to CCO at T-18:
- Full launch planning ownership
- Commercial team build and training design
- Brand strategy finalization
- Payer strategy development
- Sales force deployment planning
Delegate to CMO at T-18:
- KOL development and publication strategy
- Medical education pre-launch programming
- Medical information readiness
- Patient advocacy pre-launch engagement
Delegate to Head of Regulatory Affairs at T-18:
- FDA relationship management and submission strategy
- Label strategy development
- Advisory committee preparation if applicable
T-minus 12 Months: Readiness Assessment Delegation
At twelve months before anticipated approval, the CEO should conduct a launch readiness review that provides genuine visibility into the launch organization’s preparation without becoming a CEO-managed process.
CEO Action at T-12:
- Commission a launch readiness scorecard from the CCO covering all functional domains
- Review the scorecard and identify any gaps requiring CEO-level response (resource constraints, leadership capability gaps, cross-functional alignment failures)
- Approve any budget reallocations required to address readiness gaps
- Begin planning CEO-specific launch activities: investor day timing, payer CEO meetings, media strategy
Delegate at T-12:
- Readiness scorecard preparation: CCO and all domain leaders
- Gap remediation plans: respective domain leaders
- Payer national account strategy: Head of Market Access with CCO
- Commercial field force readiness: VP of Sales with CCO
The readiness scorecard is the CEO’s primary oversight tool at this stage. It provides structured visibility into launch preparation across all functions without requiring the CEO to attend functional launch meetings.
T-minus 6 Months: External Engagement Delegation
Six months before anticipated approval, the CEO’s attention should shift toward the external engagement work that only the CEO can do: investor preparation, payer leadership engagement, and the KOL community visibility that signals organizational confidence.
CEO Actions at T-6:
- Lead a non-deal roadshow to update key investors on the anticipated launch and commercial expectations
- Meet personally with the medical directors or pharmacy directors of the top five national payer accounts, coordinated by the Head of Market Access
- Participate in the key therapeutic area congress where the company is presenting launch-relevant data
- Finalize the investor day plan for the launch period with the Head of IR
- Review and approve the CEO’s launch day communication script
Continue Delegating at T-6:
- All commercial field readiness activities: CCO and VP of Sales
- Formulary submission management: Head of Market Access
- MSL field deployment: CMO and Head of Medical Affairs
- Trade customer readiness: Head of Commercial Operations
- Manufacturing and supply readiness: Head of Supply Chain
The T-6 CEO Rule: If the CEO is being asked to approve commercial decisions at the tactical level at T-6, the Launch Steering Committee is not functioning as intended. Use the escalation to reset the governance structure, not to solve the tactical problem personally.
Approval Day to T-plus 30 Days: Communication Delegation
The period around FDA approval is the most visible phase for the CEO. The playbook for this period:
Day of Approval:
- CEO leads all-company communication
- CEO leads investor and media communication (press release delivery, investor call)
- CEO signs personal communication to top 20 key external stakeholders (letter or email prepared by the team)
- CEO approves commercial go-live decision (based on CCO recommendation)
CEO Delegates for Approval Day:
- Press release preparation and distribution: Head of Communications and Head of IR
- Commercial field notification and mobilization: CCO and VP of Sales
- Regulatory announcement management: Head of Regulatory Affairs
- Social media and website updates: Head of Communications
- Trade customer notification: Head of Commercial Operations
According to McKinsey research on pharmaceutical launch execution, the quality of the first 30 days of a pharmaceutical launch significantly predicts first-year commercial performance. The CEO’s role in those 30 days is primarily communicative and symbolic, not operational.
T-plus 30 to T-plus 90 Days: Performance Oversight Delegation
The first 90 days of commercial activity produce critical early performance data. The CEO’s oversight role during this period operates through the weekly launch dashboard and the monthly commercial review meeting.
CEO Oversight Activities:
- Review weekly launch dashboard (15-30 minutes)
- Lead monthly commercial review meeting with CCO and launch leadership team
- Respond to any escalations from the CCO that require CEO-level decisions
- Continue external engagement: investor follow-up, key payer relationship management, high-visibility media opportunities
CEO Delegates at T+30 to T+90:
- All commercial tactical decisions: CCO
- Payer formulary management and contracting: Head of Market Access with CCO
- MSL field engagement: CMO and Head of Medical Affairs
- Sales force performance management: VP of Sales with CCO
- Any market access challenges: CCO and Head of Market Access
For a framework on how supply chain readiness supports this early commercial phase, see pharma supply chain, which covers how supply chain delegation ensures product availability through launch without CEO involvement in supply management operations.
The Launch Reporting Cadence
The CEO’s launch oversight should operate through a defined reporting cadence:
Weekly: Launch dashboard from CCO. Includes: prescription trend versus forecast, market share, coverage status, sales force performance metrics, and any significant issues. CEO review: 15-30 minutes. CEO response: flag any items requiring follow-up or escalation.
Monthly: Commercial review meeting. CEO, CCO, Head of Market Access, Head of Medical Affairs. Duration: 90 minutes. Format: structured dashboard review, issue discussion, decision-making on any CEO-level questions. CEO preparation: review the full dashboard the day before.
Quarterly: Board launch update. CEO presents launch performance summary and strategic outlook. CMO and CCO prepare the materials; CEO presents and answers questions.
When Launch Performance Disappoints
The most important delegation test in a product launch is how the CEO responds when first-quarter numbers miss forecast. The delegation playbook for underperformance:
- CEO requests a launch performance diagnosis from the CCO within 48 hours of recognizing the underperformance
- CCO presents analysis: what is driving the shortfall, whether it is structural (access, physician adoption) or executional, and what the commercial response plan is
- CEO reviews analysis, asks clarifying questions, and approves or modifies the response plan
- CEO communicates to investors and board with transparency about the shortfall and confidence in the response
- CEO returns to strategic oversight while the CCO executes the response plan
The CEO who takes over commercial management when launch underperforms rarely improves the outcome. The CEO who supports the CCO’s diagnosis and empowers their response plan is more likely to see a commercial recovery.
See pharma CEO delegation guide for a comprehensive framework connecting the product launch playbook to the full range of pharma CEO delegation responsibilities across development, regulatory, and commercial functions.
Measuring Launch Delegation Effectiveness
At the end of the launch year, the CEO should assess not just commercial performance but delegation quality. Were launch decisions made at the right level? Did the CEO’s time investment during the launch year match the delegation playbook? Were there decision bottlenecks at the CEO level that slowed commercial execution?
These reflections inform the delegation approach for the next launch cycle and for the commercial organization’s ongoing operations. Launch delegation, done well, builds commercial organizational capability that compounds across every subsequent product and indication. That is the long-term return on investing in a disciplined launch delegation playbook.
Related Reading
For further context, explore Delegation Playbook for Automotive CEO: Cost Reduction and Delegation Playbook for Automotive CEO: Crisis Management.